[Form 4] Tourmaline Bio, Inc. Insider Trading Activity
Aaron Kantoff, a director of Tourmaline Bio, Inc. (TRML), reported option exercises on 09/05/2025 that resulted in the acquisition of common stock. He exercised options to acquire 37,890 shares at an exercise price of $0.13 per share and 10,000 shares at $9.46 per share on that date. After these reported transactions the filing shows 93,281 shares beneficially owned by Mr. Kantoff on a direct basis. The filing is signed by an attorney-in-fact on behalf of the reporting person.
The filing notes the exercised options are fully vested and immediately exercisable. Transaction code "M" is recorded for both entries and the filing is a standalone Form 4 by one reporting person for TRML.
Aaron Kantoff, membro del consiglio di Tourmaline Bio, Inc. (TRML), ha comunicato l'esercizio di opzioni il 05/09/2025 che hanno portato all'acquisizione di azioni ordinarie. In quella data ha esercitato opzioni per ottenere 37.890 azioni al prezzo di esercizio di $0,13 per azione e 10.000 azioni al prezzo di $9,46 per azione. Dopo queste operazioni la dichiarazione indica che il sig. Kantoff detiene 93.281 azioni a titolo diretto. Il documento 猫 stato firmato da un procuratore in nome del dichiarante.
Si precisa che le opzioni esercitate erano pienamente maturate e immediatamente esercitabili. Per entrambe le operazioni 猫 riportato il codice transazione "M" e si tratta di un Form 4 indipendente presentato da un unico soggetto per TRML.
Aaron Kantoff, director de Tourmaline Bio, Inc. (TRML), inform贸 ejercicios de opciones el 05/09/2025 que dieron lugar a la adquisici贸n de acciones comunes. Ese d铆a ejerci贸 opciones para adquirir 37.890 acciones a un precio de ejercicio de $0,13 por acci贸n y 10.000 acciones a $9,46 por acci贸n. Tras estas operaciones, la presentaci贸n muestra que el Sr. Kantoff posee 93.281 acciones con titularidad directa. El documento est谩 firmado por un apoderado en nombre de la persona informante.
La presentaci贸n indica que las opciones ejercidas estaban completamente adquiridas y eran ejercitables de inmediato. Para ambas entradas figura el c贸digo de transacci贸n "M" y se trata de un Form 4 independiente presentado por una sola persona informante para TRML.
韴柎毵愲Π 氚旍澊鞓�(Tourmaline Bio, Inc., TRML) 鞚挫偓鞚� 鞎勲 旃疙啝頂�(Aaron Kantoff)電� 2025-09-05鞐� 旖滌樀靺� 頄夓偓搿� 氤错喌欤茧ゼ 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 鞚检瀽鞐� 攴鸽姅 頄夓偓臧�瓴� 欤茧嫻 $0.13鞙茧 37,890欤�, 欤茧嫻 $9.46鞙茧 10,000欤茧ゼ 頄夓偓頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 鞝滌稖靹滊鞐愲姅 旃疙啝頂� 鞌皜 歆侅爲 氤挫湢頃� 欤检嫕鞚� 93,281欤�搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊姅 氤搓碃鞚胳潉 雽�鞁犿暣 氩曥爼雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
鞝滌稖靹滌棎電� 頄夓偓霅� 鞓奠厴鞚� 鞕勳爠頌� 氩犾姢韺呺悩鞏� 歃夓嫓 頄夓偓 臧�電ロ晿雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 霊� 瓯半灅 氇憪鞐� 瓯半灅 旖旊摐 "M"鞚� 旮办灛霅橃柎 鞛堨溂氅�, TRML鞐� 雽�頃� 頃� 氇呾潣 氤搓碃鞚胳澊 雼弲鞙茧 鞝滌稖頃� Form 4鞛呺媹雼�.
Aaron Kantoff, administrateur de Tourmaline Bio, Inc. (TRML), a d茅clar茅 l'exercice d'options le 05/09/2025, entra卯nant l'acquisition d'actions ordinaires. 脌 cette date, il a exerc茅 des options pour acqu茅rir 37 890 actions au prix d'exercice de 0,13 $ par action et 10 000 actions au prix de 9,46 $ par action. Apr猫s ces op茅rations d茅clar茅es, le d茅p么t indique que M. Kantoff d茅tient 93 281 actions en propri茅t茅 directe. Le document est sign茅 par un mandataire au nom de la personne d茅clarante.
Le d茅p么t pr茅cise que les options exerc茅es 茅taient enti猫rement acquises et imm茅diatement exer莽ables. Le code de transaction "M" est enregistr茅 pour les deux lignes et il s'agit d'un formulaire 4 autonome d茅pos茅 par une seule personne d茅clarante pour TRML.
Aaron Kantoff, Vorstandsmitglied von Tourmaline Bio, Inc. (TRML), meldete Optionsaus眉bungen am 05.09.2025, die zum Erwerb von Stammaktien f眉hrten. An diesem Datum 眉bte er Optionen zum Erwerb von 37.890 Aktien zum Aus眉bungspreis von $0,13 je Aktie und 10.000 Aktien zum Preis von $9,46 je Aktie aus. Nach diesen gemeldeten Transaktionen weist die Meldung aus, dass Herr Kantoff 93.281 Aktien unmittelbar besitzt. Das Formular ist von einem Bevollm盲chtigten im Namen der meldenden Person unterzeichnet.
In der Meldung wird darauf hingewiesen, dass die ausge眉bten Optionen vollst盲ndig unverfallbar und sofort aus眉bbar waren. F眉r beide Eintr盲ge ist der Transaktionscode "M" vermerkt; es handelt sich um ein eigenst盲ndiges Form 4 einer einzigen meldenden Person f眉r TRML.
- Reporting person acquired 37,890 shares at $0.13 and 10,000 shares at $9.46 through option exercises on 09/05/2025.
- The filing states the options were fully vested and immediately exercisable, and the report was filed by one reporting person.
- Post-transaction direct beneficial ownership is 93,281 shares as reported on the Form 4.
- None.
Insights
TL;DR: Director exercised vested options and increased direct shareholdings to 93,281 shares.
The Form 4 documents two option exercises by a Tourmaline Bio director on 09/05/2025. Both exercises are reported with transaction code M and the filing explicitly states the options were fully vested and immediately exercisable. The exercises converted 47,890 option units into common stock at exercise prices of $0.13 and $9.46 per share. This filing is procedural and complies with Section 16 reporting: it records change in beneficial ownership rather than a discretionary open-market purchase or sale. For governance review, the key facts are vesting status, exercise prices, and resulting direct ownership level of 93,281 shares.
TL;DR: Two option exercises added 47,890 shares to direct holdings; no derivative holdings reported after the transactions.
The Form 4 shows exercises on 09/05/2025 that resulted in acquisition entries in both the non-derivative and derivative tables: 37,890 units at $0.13 and 10,000 units at $9.46. The derivative table records the underlying common stock amounts and lists zero derivative securities beneficially owned following the transactions, consistent with conversion of options into shares. The filing does not disclose sales, pledges, or other dispositions, and is limited to these exercises and the post-transaction direct ownership total.
Aaron Kantoff, membro del consiglio di Tourmaline Bio, Inc. (TRML), ha comunicato l'esercizio di opzioni il 05/09/2025 che hanno portato all'acquisizione di azioni ordinarie. In quella data ha esercitato opzioni per ottenere 37.890 azioni al prezzo di esercizio di $0,13 per azione e 10.000 azioni al prezzo di $9,46 per azione. Dopo queste operazioni la dichiarazione indica che il sig. Kantoff detiene 93.281 azioni a titolo diretto. Il documento 猫 stato firmato da un procuratore in nome del dichiarante.
Si precisa che le opzioni esercitate erano pienamente maturate e immediatamente esercitabili. Per entrambe le operazioni 猫 riportato il codice transazione "M" e si tratta di un Form 4 indipendente presentato da un unico soggetto per TRML.
Aaron Kantoff, director de Tourmaline Bio, Inc. (TRML), inform贸 ejercicios de opciones el 05/09/2025 que dieron lugar a la adquisici贸n de acciones comunes. Ese d铆a ejerci贸 opciones para adquirir 37.890 acciones a un precio de ejercicio de $0,13 por acci贸n y 10.000 acciones a $9,46 por acci贸n. Tras estas operaciones, la presentaci贸n muestra que el Sr. Kantoff posee 93.281 acciones con titularidad directa. El documento est谩 firmado por un apoderado en nombre de la persona informante.
La presentaci贸n indica que las opciones ejercidas estaban completamente adquiridas y eran ejercitables de inmediato. Para ambas entradas figura el c贸digo de transacci贸n "M" y se trata de un Form 4 independiente presentado por una sola persona informante para TRML.
韴柎毵愲Π 氚旍澊鞓�(Tourmaline Bio, Inc., TRML) 鞚挫偓鞚� 鞎勲 旃疙啝頂�(Aaron Kantoff)電� 2025-09-05鞐� 旖滌樀靺� 頄夓偓搿� 氤错喌欤茧ゼ 旆摑頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 鞚检瀽鞐� 攴鸽姅 頄夓偓臧�瓴� 欤茧嫻 $0.13鞙茧 37,890欤�, 欤茧嫻 $9.46鞙茧 10,000欤茧ゼ 頄夓偓頄堨姷雼堧嫟. 鞚� 瓯半灅 鞚错泟 鞝滌稖靹滊鞐愲姅 旃疙啝頂� 鞌皜 歆侅爲 氤挫湢頃� 欤检嫕鞚� 93,281欤�搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊姅 氤搓碃鞚胳潉 雽�鞁犿暣 氩曥爼雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
鞝滌稖靹滌棎電� 頄夓偓霅� 鞓奠厴鞚� 鞕勳爠頌� 氩犾姢韺呺悩鞏� 歃夓嫓 頄夓偓 臧�電ロ晿雼り碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 霊� 瓯半灅 氇憪鞐� 瓯半灅 旖旊摐 "M"鞚� 旮办灛霅橃柎 鞛堨溂氅�, TRML鞐� 雽�頃� 頃� 氇呾潣 氤搓碃鞚胳澊 雼弲鞙茧 鞝滌稖頃� Form 4鞛呺媹雼�.
Aaron Kantoff, administrateur de Tourmaline Bio, Inc. (TRML), a d茅clar茅 l'exercice d'options le 05/09/2025, entra卯nant l'acquisition d'actions ordinaires. 脌 cette date, il a exerc茅 des options pour acqu茅rir 37 890 actions au prix d'exercice de 0,13 $ par action et 10 000 actions au prix de 9,46 $ par action. Apr猫s ces op茅rations d茅clar茅es, le d茅p么t indique que M. Kantoff d茅tient 93 281 actions en propri茅t茅 directe. Le document est sign茅 par un mandataire au nom de la personne d茅clarante.
Le d茅p么t pr茅cise que les options exerc茅es 茅taient enti猫rement acquises et imm茅diatement exer莽ables. Le code de transaction "M" est enregistr茅 pour les deux lignes et il s'agit d'un formulaire 4 autonome d茅pos茅 par une seule personne d茅clarante pour TRML.
Aaron Kantoff, Vorstandsmitglied von Tourmaline Bio, Inc. (TRML), meldete Optionsaus眉bungen am 05.09.2025, die zum Erwerb von Stammaktien f眉hrten. An diesem Datum 眉bte er Optionen zum Erwerb von 37.890 Aktien zum Aus眉bungspreis von $0,13 je Aktie und 10.000 Aktien zum Preis von $9,46 je Aktie aus. Nach diesen gemeldeten Transaktionen weist die Meldung aus, dass Herr Kantoff 93.281 Aktien unmittelbar besitzt. Das Formular ist von einem Bevollm盲chtigten im Namen der meldenden Person unterzeichnet.
In der Meldung wird darauf hingewiesen, dass die ausge眉bten Optionen vollst盲ndig unverfallbar und sofort aus眉bbar waren. F眉r beide Eintr盲ge ist der Transaktionscode "M" vermerkt; es handelt sich um ein eigenst盲ndiges Form 4 einer einzigen meldenden Person f眉r TRML.
FAQ
What did Aaron Kantoff (TRML) report on Form 4?
What is the significance of transaction code M on this TRML Form 4?
Are the exercised options vested for the TRML reporting person?
How many total shares were acquired in the reported transactions for TRML?
Who signed the Form 4 for the TRML reporting person?
